Companies · Other Health Care

StrokeDx, Inc.

Pasadena · Other Health Care

Diligence memoA one-page analyst read on StrokeDx, Inc. — recommendation, valuation, rhythm, risks.
$6.0M
Total raised · real
2
Rounds
2.5×
Latest step-up
Top 33%
Sector rank · raised
Series A
Latest stage · inferred · Thu May 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

StrokeDx, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.59× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.
Quiet
  • Last raise 2.1 yr ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

StrokeDx, Inc. is one of 5377 Other Health Care companies tracked from Pasadena. By capital raised it ranks mid-pack (ahead of 68% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2022
Year incorporated
2024-05-23
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MSeed · 2022-10-12 Raised $1.7M (real) Modeled valuation $16M (est)$1.7M$16MSeed2022Series A · 2024-05-23 Raised $4.3M (real) Modeled valuation $22M (est)$4.3M$22MSeries A2024+$4.3MCumulative $6.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.7M · 2022
Series A$4.3M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$21.6M
Base estimate est.
$5.5M
Conservative case
$48.0M
Upside case
$19.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $15.8M · 2022-10-122022Series A · modeled $21.6M · 2024-05-232024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
2.1 yr
Elapsed time used
2.1 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
19 mo
Avg between rounds
$3.7M/yr
Capital velocity
3.7 yr
On record since
2022
First round
2
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.5× above median
This company$6.0M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.8× of median
This company$4.3M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 1.0× of median
This company$21.6M
Sector median$22.1M

Raised more than 68% of sector peers (real $). Modeled value above 50% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #146 of 196.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)CareHarmony, Inc. · Series A Raised $17.4M · modeled $145.2M (est)Dragonfly Endoscopy Inc. · Series A Raised $12.7M · modeled $142.0M (est)NuvoAir Holdings, Inc. · Series A Raised $10.7M · modeled $125.1M (est)Post Acute Recovery, Inc. · Series A Raised $14.5M · modeled $123.0M (est)Micro Interventional Devices, Inc. · Series A Raised $14.0M · modeled $119.0M (est)Etiometry Inc. · Series A Raised $15.6M · modeled $114.7M (est)SafKan, Inc. · Series A Raised $13.0M · modeled $108.5M (est)BehaVR Holdings, Inc. · Series A Raised $12.1M · modeled $102.1M (est)Outliers Inc. · Series A Raised $13.6M · modeled $101.7M (est)RevMedica, Inc. · Series A Raised $14.2M · modeled $101.2M (est)Innovoyce LLC · Series A Raised $9.9M · modeled $97.6M (est)Prixz, Inc. · Series A Raised $9.2M · modeled $97.4M (est)StrokeDx, Inc. (this company) Raised $6.0M · modeled $21.6M (est)StrokeDx, Inc.
CompanyStageRaised · realValue · estvs peer med.
CareHarmony, Inc.Series A$17.4M$145.2M3.96×
Dragonfly Endoscopy Inc.Series A$12.7M$142.0M3.87×
NuvoAir Holdings, Inc.Series A$10.7M$125.1M3.41×
Post Acute Recovery, Inc.Series A$14.5M$123.0M3.35×
Micro Interventional Devices, Inc.Series A$14.0M$119.0M3.25×
Etiometry Inc.Series A$15.6M$114.7M3.13×
SafKan, Inc.Series A$13.0M$108.5M2.96×
BehaVR Holdings, Inc.Series A$12.1M$102.1M2.78×
Outliers Inc.Series A$13.6M$101.7M2.77×
RevMedica, Inc.Series A$14.2M$101.2M2.76×
Innovoyce LLCSeries A$9.9M$97.6M2.66×
Prixz, Inc.Series A$9.2M$97.4M2.66×
StrokeDx, Inc. this companySeries A$6.0M$21.6M0.59×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.7M2022-10-12$8.5M$15.8M90%
Series A$4.3M2024-05-23$19.7M$21.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.7M2022-10-12
    • First recorded raise — entered as Seed.
    • 5 investors on this round.
  2. Series A$4.3M2024-05-23
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
    • 3 investors on this round.
Intelligence
2026 ~Q1
Modeled next raise · ~19mo cadence
$11.0M
Modeled next size est.range $7.2M$17.6M
2.5×
Last step-up
$3.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kevin Barrett4 other2024-05
Alexander Ballatori2022-10
Shane Shahrestani2022-10
Registry & provenance

StrokeDx, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1950973
SEC CIK
2022
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
PolyRemedy IncOther Health CareSeries A$13.7M$10.9Mnetwork1 shared operator · same sector · same stage
Bexa Inc.Other Health CareSeries A$6.0M$24.6Msame sector · same stage
Rebel Medicine IncOther Health CareSeries A$6.1M$23.5Msame sector · same stage
AdvocateMH Inc.Other Health CareSeries A$6.2M$23.8Msame sector · same stage
Certara, Inc.Other Health CareSeries A$5.7M$21.0Msame sector · same stage
Nanox Imaging plc.Other Health CareSeries A$6.7M$22.3Msame sector · same stage
Twinlab Consolidated Holdings, Inc.Other Health CareSeries A$6.7M$20.2Msame sector · same stage
Voyager Biomedical, Inc.Other Health CareSeries A$6.8M$21.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
FundRx, Inc.Other Health CareSeed$34.5M87%
BioMedx Group, Inc.Other Health CarePre-Seed$14.0M86%
Remedtx, Inc.Other Health CarePre-Seed$1.4M86%
Thrombolex, Inc.Other Health CareSeries B$129.3M86%
Medico CX, Inc.Other Health CarePre-Seed$10.1M86%
MovementX, Inc.Other Health CarePre-Seed$3.1M85%
Choix, Inc.Other Health CarePre-Seed$12.2M85%
FlexDex, Inc.Other Health CareSeries A$11.9M85%
Frequently asked
How much funding has StrokeDx, Inc. raised?
StrokeDx, Inc. has raised approximately $6.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is StrokeDx, Inc.'s estimated valuation?
Provath's modeled valuation for StrokeDx, Inc. is approximately $21.6M (modeled range $5.5M–$48.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is StrokeDx, Inc. at?
StrokeDx, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu May 23.
What does StrokeDx, Inc. do and where is it based?
StrokeDx, Inc. operates in the Other Health Care sector, based in Pasadena.
Explore related

See where StrokeDx, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at StrokeDx, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.